Angela M DeMichele, MD, MSCE, FASCO
Mariann T. and Robert J. MacDonald Professor in Breast Cancer Care Excellence
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Co-Leader, Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania
Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
Director of Clinical/Translational Research in Solid Oncology, Division of Hematology/Oncology, University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-153
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-153
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
Fax: 215-615-3349
Education:
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Permanent linkB.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Description of Research Expertise
breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiologyDescription of Clinical Expertise
breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorshipSelected Publications
Huppert, L. A., Wolf, D., Yau, C., Brown-Swigart, L., Hirst, G. L., Isaacs, C., Pusztai, L., Pohlmann, P. R., DeMichele, A., Shatsky, R., Yee, D., Thomas, A., Nanda, R., Perlmutter, J., Heditsian, D., Hylton, N., Symmans, F., Van't Veer, L. J., Esserman, L., & Rugo, H. S. : Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Annals of Oncology Feb 2025 Notes: https://doi.org/10.1016/j.annonc.2024.10.018.Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, Bonnefoi H, Kim S, Seiler S, Bear HD, Witkiewicz AK, Im S, DeMichele A, Pehl A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff CC, Kelly CM, Reimer T, Felder B, Olivé MM, Knudsen ES, Turner N, Rojo F, Schmitt WD, Fasching PA, Teply-Szymanski J, Zhang Z, Toi M, Rugo HS, Gnant M, Makris A, Holtschmidt J, Nekljudova V, Loibl S: Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping. Cancer Cell Feb 2025.
Magbanua MJM., Ahmed Z., Sayaman RW., Swigart LB., Hirst GL., Yau C., Wolf DM., Li W., Delson AL., Perlmutter J., Pohlmann P., Symmans WF., Yee D., Hylton NM., Esserman LJ., DeMichele A., Rugo HS., van 't Veer LJ. : Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy Clin Cancer Res Apr 2024.
Mayer EL., Ren Y., Wagle N., Mahtani R., Ma C., DeMichele A., Cristofanilli M., Meise J., Kathy D Miller KD., Abdou Y., Riley EC., Qamar R., Sharma P., Reid S., Sinclair N., Faggen M., Block CC., Ko N., Partridge AH., Chen WY., DeMeo M., Attaya V., Amanda Okpoebo A., Alberti J., Liu Y., Gauthier E., Burstein HJ., Regan MM., Tolaney SM: PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. J Clin Oncol Mar 2024.
Lawrence-Paul MR, Pan T, Pant DK, Chen Y, Belka GK, Feldman M, DeMichele A, Chodosh LA: Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination. Genome Medicine Feb 2024.
Albain KS., Yau C., Petricoin EF., Wolf DM., Lang JE., Chien AJ., Haddad T., Forero-Torres A., Wallace AM., Kaplan H., Pusztai L., Euhus D., Nanda R., Elias AD., Clark AS., Godellas C., Boughey JC., Isaacs C., Tripathy D., Lu J., Yung RL., Gallagher R., Wulfkuhle JD., Brown-Swigart L., Krings G., Chen YY., Potter DA., Stringer-Reasor E., Blair S., Asare SM., Wilson A., Hirst GL., Singhrao R., Buxton M., Clennell JL., Sanil A., Berry S., Asare AL., Matthews JB., DeMichele A., Hylton NM., Melisko M., Perlmutter J., Rugo HS., Symmans WF., Van't Veer LJ., Yee D., Berry DA., Esserman LJ: Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res Feb 2024.
Smith KL., Zhao F., Mayer IA., Tevaarwerk AJ., Garcia SF., Arteaga CL., Symmans WF., Park BH., Burnette BL., Makower DF., Block M., Morley KA., Jani CR., Mescher C., Shabana J Dewani SJ., Brown-Glaberman U., Flaum LE., Mayer EL., Sikov WM., Rodler ET., DeMichele A., Sparano JA., Wolff AC., Miller KD., Wagner LI : Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131 Cancer Jan 2024.
Albain KS, Yau C, Petricoin EF, Lang JE, Chein AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Swigart LB, Krings G, Chen YY, Potter DA, Stringer-Reason E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton A, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ: Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clin Cancer Res Dec 2023.
Gallagher RI., Wulfkuhle J., Wolf DM., Brown-Swigart L., Yau C., O'Grady N., Amrita Basu A., Lu R., Campbell MJ., Magbanua MJ., Coppé JP., I-SPY 2 Investigators; Asare SM., Sit L., Matthews JB., Perlmutter J., Hylton N., Liu MC., Symmans WF., Rugo HS., Isaacs C., DeMichele A., Yee D., Pohlmann PR., Hirst GL., Esserman LJ., van 't Veer LJ., Petricoin EF : Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial Cell Rep Med Dec 2023.
Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chein AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edminston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele A, Van't Veer LJ, Esserman LJ, Olopade OI: Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Network Open Dec 2023.